Published in Infect Immun on July 01, 1985
Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J Exp Med (1989) 1.49
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Infect Immun (2004) 1.09
Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection. Infect Immun (2012) 0.97
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Mouse lymphocytes with and without surface immunoglobulin: preparative scale separation in polystyrene tissue culture dishes coated with specifically purified anti-immunoglobulin. J Immunol Methods (1977) 8.43
Genetic analysis of phase change in Bordetella pertussis. Infect Immun (1984) 5.03
Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. J Immunol (1981) 4.04
Characterization of the macrophage receptro for complement and demonstration of its functional independence from the receptor for the Fc portion of immunoglobulin G. J Exp Med (1975) 3.80
Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis. Rev Infect Dis (1980) 3.34
Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun (1981) 3.16
Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect Immun (1981) 2.94
Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect Immun (1981) 2.77
A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J Biol Chem (1983) 2.65
Islets-activating protein (IAP) in Bordetella pertussis that potentiates insulin secretory responses of rats. Purification and characterization. J Biochem (1978) 2.26
Gamma-interferon is one of several direct B cell-maturing lymphokines. Nature (1984) 2.18
Relative ability of mitogens to stimulate production of interferon by lymphoid cells and to induce suppression of the in vitro immune response. Proc Soc Exp Biol Med (1977) 2.07
The effect of staphylococcal enterotoxins on the primary in vitro immune response. J Immunol (1975) 1.88
Role of gamma-interferon in antibody-producing responses. Nature (1984) 1.87
A skin-sensitizing and thermolabile antibody in the mouse. Life Sci (1966) 1.79
Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun (1983) 1.77
Interferons with special emphasis on the immune system. Adv Immunol (1983) 1.69
The effect of pertussis vaccine on the immune response of mice to sheep red blood cells. Clin Exp Immunol (1970) 1.56
Interferon nomenclature. Nature (1980) 1.53
Crystallization of pertussigen from Bordetella pertussis. Infect Immun (1981) 1.45
In vitro production and cellular origin of murine type II interferon. Immunology (1979) 1.39
The in vitro effects of Bordetella pertussis lymphocytosis-promoting factor on murine lymphocytes. I. Proliferative response. J Exp Med (1977) 1.28
The in vitro effects of Bordetella pertussis lymphocytosis-promoting factor on murine lymphocytes: II. Nature of the responding cells. J Exp Med (1977) 1.23
Effects of the lymphocytosis-promoting factor of Bordetella pertussis on antibody production in mice. Jpn J Med Sci Biol (1969) 1.03
Adjuvant effect of Bordetella pertussis vaccine to sheep erythrocytes: enhancement of antibody formation by using subcutaneous administration of adjuvant and antigen. Infect Immun (1975) 1.02
Proliferative response of immune mouse T-lymphocytes to the lymphocytosis-promoting factor of Bordetella pertussis. Infect Immun (1984) 0.95
Cellular regulation of gamma interferon production: Lyt phenotype of the suppressor cell. Infect Immun (1982) 0.95
The effect of pertussis adjuvant on antibody production: the need for thymus-dependent lymphocytes. Eur J Immunol (1973) 0.93
Mitogenic response of C3H/HeJ mouse lymphocytes to polyanionic polysaccharides obtained from Bordetella pertussis endotoxin and from other bacterial species. Infect Immun (1981) 0.93
Immunologic and biochemical properties of the histamine-sensitizing factor from Bordetella pertussis. J Immunol (1975) 0.86
Antibody formation against 2,4-dinitrophenyl-hapten at the cellular level. Hemolytic plaque-in-gel assay for lymphoid cells producing anti-2,4-dinitrophenyl-hapten antibody. J Immunol (1969) 0.84
Characteristics of alloantigens and cellular mechanisms responsible for gamma-interferon production in primary murine MLC. J Interferon Res (1981) 0.82
Preferential enhancement of IgE antibody formation by Bordetella pertussis. Int Arch Allergy Appl Immunol (1977) 0.82
Recombinant mouse interferon-gamma regulation of antibody production. Infect Immun (1983) 0.81
Subunit structure of islets-activating protein (IAP), a new protein isolated from the culture media of Bordetella pertussis. J Biochem (1978) 0.81
Interferon production by Bordetella pertussis components in rabbits and in rabbit cell cultures. Jpn J Microbiol (1973) 0.80
Effects of Bordetella pertussis components on IgE and IgG1 responses. Microbiol Immunol (1983) 0.79
Effect of lymphocytosis-promoting factor (LPF) on the appearnace of antibodies in mice infected with influenza virus. J Immunol (1970) 0.77
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med (1999) 6.91
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol (1992) 4.85
Priming: a nonantiviral function of interferon. J Virol (1971) 2.95
A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet (1990) 2.89
Cancer patients' perceptions of their disease and its treatment. Br J Cancer (1988) 2.66
NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol (1994) 2.40
Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol (1986) 2.37
Growth of Legionella pneumophila in thioglycolate-elicited peritoneal macrophages from A/J mice. Infect Immun (1988) 2.37
Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol (2005) 2.32
The importance of measuring cotinine levels to identify smokers in clinical trials. Clin Pharmacol Ther (1994) 2.11
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis (2000) 2.07
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. Oncogene (2000) 2.07
Relative sensitivities of viruses to different species of interferon. J Virol (1969) 2.02
Direct localization and visualization of hyaluronate lyase activity by agar gel electrophoresis. Proc Soc Exp Biol Med (1967) 2.00
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys (1999) 1.96
Neurodevelopment and predictors of outcomes of children with birth weights of less than 1000 g: 1992-1995. Arch Pediatr Adolesc Med (2000) 1.95
Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. Proc Natl Acad Sci U S A (1981) 1.89
Enhanced susceptibility of penicillin-resistant staphylococci to phagocytosis after in vitro incubation with low doses of nafcillin. Proc Soc Exp Biol Med (1974) 1.76
Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet (1999) 1.75
Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol (2001) 1.74
Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol (1988) 1.73
Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J Virol (2000) 1.73
Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Immunol (1988) 1.70
Differences in HLA class II alleles of isolated South American Indian populations from Brazil and Argentina. Hum Immunol (1993) 1.69
Four cases of postrenal renal failure induced by renal stone associated with rotavirus infection. Clin Nephrol (2010) 1.65
Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol (1990) 1.65
Current status of immunological adjuvants. Annu Rev Immunol (1986) 1.65
Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol (1986) 1.62
Effects of RES "blockade" on antibody-formation. I. Suppressed cellular and humoral haemolysin responses in mice injected with carbon particles. Immunology (1969) 1.61
Radiometric detection of bacteremia: requirement for terminal subcultures. J Clin Microbiol (1977) 1.61
Bacterial heat shock proteins directly induce cytokine mRNA and interleukin-1 secretion in macrophage cultures. Infect Immun (1994) 1.54
Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C. J Gastroenterol (1998) 1.49
Cryptococcal capsular polysaccharide-induced modulation of murine immune responses. Infect Immun (1982) 1.47
N-(3',4'-dimethoxycinnamoyl)anthranillic acid, an antiallergic compound, induced eosinophilic cystitis. Urol Int (1986) 1.46
Fatigue in Parkinson's disease. Neurology (1993) 1.46
A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium. J Biol Chem (1994) 1.46
Identification of the cell multiplication inhibitory factors in interferon preparations as interferons. Nature (1976) 1.41
Familial isolated hypoparathyroidism: a molecular genetic analysis of 8 families with 23 affected persons. Medicine (Baltimore) (1986) 1.40
Legionella pneumophila-induced blastogenesis of murine lymphoid cells in vitro. Infect Immun (1984) 1.39
Building collaborative relationships with families of the mentally ill. Hosp Community Psychiatry (1988) 1.38
Variability of X-ray emission from M87. Nature (1971) 1.38
Vibrio vulnificus resists phagocytosis in the absence of serum opsonins. Infect Immun (1985) 1.35
Quantification of thymic function by measuring T cell receptor excision circles within peripheral blood and lymphoid tissues in monkeys. Eur J Immunol (2000) 1.35
Temperature control of initiation of protein synthesis in Escherichia coli. J Mol Biol (1971) 1.32
Immunosuppressive effects of Friend and Rauscher leukemia disease viruses on cellular and humoral antibody formation. J Natl Cancer Inst (1968) 1.31
Enhancement of human monocyte function against Candida albicans by the colony-stimulating factors (CSF): IL-3, granulocyte-macrophage-CSF, and macrophage-CSF. J Immunol (1989) 1.30
Production, partial purification and characterization of human and murine interferons--type II. Mol Immunol (1980) 1.29
Outcomes of extremely low birth weight infants. Pediatrics (1996) 1.28
Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol (2000) 1.28
Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta. Brain Behav Immun (1995) 1.28
The cannabinoid system and cytokine network. Proc Soc Exp Biol Med (2000) 1.27
Distinct molecular species of interferons. Virology (1974) 1.27
Inhibition of Legionella pneumophila growth by gamma interferon in permissive A/J mouse macrophages: role of reactive oxygen species, nitric oxide, tryptophan, and iron(III). Infect Immun (1994) 1.27
Viral hepatitis, type A. Identification by specific complement fixation and immune adherence tests. N Engl J Med (1975) 1.25
An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue Antigens (1997) 1.24
Population study of triazolam pharmacokinetics. Br J Clin Pharmacol (1986) 1.24
Immunosuppression by leukemia viruses. I. Effect of Friend disease virus on cellular and humoral hemolysin responses of mice to a primary immunization with sheep erythrocytes. J Immunol (1968) 1.23
Molecular heterogeneity of human leukocyte interferon: two populations differing in molecular weights, requirements for renaturation, and cross-species antiviral activity. Virology (1975) 1.23
Assessment of gadolinium-enhanced time-resolved three-dimensional MR angiography for evaluating renal artery stenosis. AJR Am J Roentgenol (2001) 1.23
Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol (1999) 1.23
Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol (1997) 1.22
Differential growth of Legionella pneumophila in guinea pig versus mouse macrophage cultures. Infect Immun (1987) 1.21
Marijuana, immunity and infection. J Neuroimmunol (1998) 1.21
Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun (1994) 1.21
Differential complement activation and susceptibility to human serum bactericidal action by Vibrio species. Infect Immun (1983) 1.20
Variation in antigenic determinants of p53 transformation-related protein obtained from various species. J Immunol (1983) 1.19
Dorsal column stimulation for control of pain. Preliminary report on 30 patients. J Neurosurg (1972) 1.18
Streptococcus mutans strains harboring collagen-binding adhesin. J Dent Res (2004) 1.18
Cannabinoid receptors and immunity. Immunol Today (1998) 1.17
Comparison of a radiometric procedure with conventional methods for identification of Neisseria. J Clin Microbiol (1978) 1.17
Induction of interferon-gamma and tumor necrosis factor by Legionella pneumophila: augmentation of human neutrophil bactericidal activity. J Leukoc Biol (1989) 1.17
Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol (1990) 1.17
MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR Am J Roentgenol (1994) 1.17
Lymphoepithelial cysts in the mediastinum with an opening to the trachea. Respiration (1995) 1.16
Molecular modification of interferon: attainment of human interferon in a conformation active on cat cells but inactive on human cells. Virology (1976) 1.16
Electromicturition in paraplegia. Implantation of a spinal neuroprosthesis. Arch Surg (1972) 1.15
Distinguishing characteristics of the interferon responses of primary and continuous mouse cell cultures. J Gen Virol (1971) 1.15
5'-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J Biol Chem (1988) 1.14
Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extracts. J Immunol (1975) 1.14
Cytolytic activity of human peripheral blood leukocytes against Legionella pneumophila-infected monocytes: characterization of the effector cell and augmentation by interleukin 2. J Immunol (1987) 1.14